The Fred & Pamela Buffett Cancer Center boasts an impressive list of ground-breaking milestones in the fight against cancer.
Every breakthrough in research, every advancement in patient care, every first on campus has lead to this revolutionary new era for the Fred & Pamela Buffett Cancer Center.
Eugene Eppley Foundation establishes the Eppley Institute for Research in Cancer and begins construction of the first research building at UNMC dedicated to cancer research.
Henry Lemon, M.D., was recruited from Boston as the first Director of the Eppley Institute. Under his leadership, Eppley Institute developed multidisciplinary clinical and laboratory research programs focused on the causes of cancer and new approaches to improve the diagnosis, treatment and prevention of cancer.
Philippe Shubik, M.D. an internationally recognized leader in carcinogenesis, was recruited from the Chicago Medical School and becomes the second Director of the Eppley Institute. Dr. Shubik, a member of the National Cancer Institute’s National Cancer Advisory Board, expanded research programs at UNMC with a particular focus on the identification of carcinogens and an emphasis on experimental pathology and biochemistry.
First bone marrow transplant.
Eppley Institute was awarded a Cancer Center Support Grant (CCSG) from the National Cancer Institute, and became one of 13 Laboratory Cancer Research Centers in the United States.
First peripheral stem cell transplant program founded.
University of Nebraska Board of Regents established the Cancer Center as a university-wide matrix cancer center responsible for coordinating all cancer research activities at the University of Nebraska.
Kenneth Cowan, M.D., Ph.D. becomes Director of the Cancer Center and the Eppley Institute for Research in Cancer and Allied Diseases. Dr. Cowan previously served 21 years in leadership positions at the National Cancer Institute in the Clinical Pharmacology Branch and Medicine Branch at NCI. His research involved studies in mechanisms of drug resistance in breast cancer and clinical investigations in breast cancer. He served as the Chief of the Medical Breast Cancer Section at NCI from 1988-1999.
First Intensity Modulated Radiation Therapy (IMRT) to treat cancer.
First Novalis Radiation Therapy System in Region. Novalis Radiosurgery consists of a high-tech radiation delivery system powered by innovative, sophisticated image-guidance and motion management tools. This state-of-the-art system rotates around you, from many different angles, delivering the cancer-fighting shaped treatment beams where they’re needed. The image-guidance and motion management tools provide your doctors with detailed information about the shape, size and position of your tumor, they also guide setup and positioning, and monitor your body and tumor motion during treatment.
The Cancer Center becomes one of 18 academic research centers participating in an RNAi Global Initiative using a library of 88,000 RNAi oligonucleotides from 22,000 different genes developed by Dharmacon. Through collaboration and the meaningful exchange of information and data, the Cancer Center starts to draw a comprehensive roadmap of human gene function and use this as a foundation to revolutionize the way medicine and healthcare are delivered.
First Calypso 4-D Localization System for Radiation Therapy in Region. A new kind of radiation therapy is targeting cancer the same way a Global Positioning System, or GPS, pinpoints the location of your car. The Calypso 4D Localization System is now being offered to prostate cancer patients at The Nebraska Medical Center, one of only five medical centers worldwide to attain the Calypso technology.
Cancer Center receives state support to add an industrial robotic platform, shaking incubators, an Illuminex reader and high-throughout digital microscopy. State-of-the art High-Throughput Screening Facility (HTSF) with genome-wide RNAi library screening provides Cancer Center members new opportunities for target identification in cancer cells while chemical library screening will provide opportunities to identify new small molecule inhibitors and potential new drugs for cancer treatment.
First Blue Distinction Center for Rare & Complex Cancers.
Village Pointe Cancer Center opens. The new West Omaha Cancer Clinic contains 60,000 square feet of outpatient multidisciplinary clinics (medical, surgical and radiation oncology), infusion center, outpatient surgical suites, radiation therapy facilities, and a clinical trials office.
(May) – Ground breaking at the site of the new Fred & Pamela Buffett Cancer Center.
(June) – University of Nebraska Board of Regents approve changing the name of the UNMC Eppley Cancer Center to the Fred & Pamela Buffett Cancer Center.
Julie Vose, MD, elected president of the American Society of Clinical Oncology (ASCO) for a one-year term beginning in June 2015.Since joining ASCO in 1991, Dr. Vose has served on the board of directors as chair of the Cancer Education Committee and is the current chair-elect of the Integrated Media and Technology Committee, among other activities.